Akonur Alp, Holmes Clifford J, Leypoldt John K
Medical Products R&D (Innovation), Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015, USA.
Medical Products R&D (Renal), Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015, USA.
Perit Dial Int. 2015 May-Jun;35(3):288-96. doi: 10.3747/pdi.2012.00247. Epub 2014 Mar 1.
Contrary to ultrafiltration, the three-pore model predictions of icodextrin absorption from the peritoneal cavity have not yet been reported likely, in part, due to difficulties in estimating the degradation of glucose-polymer chains by α-amylase activity in dialysate. We incorporated this degradation process in a modified three-pore model of peritoneal transport to predict ultrafiltration and icodextrin absorption simultaneously in rats and humans.
Separate three-pore models were constructed for humans and rats. The model for humans was adapted from PD Adequest 2.0 including a clearance term out of the peritoneal cavity to account for the absorption of large molecules to the peritoneal tissues, and considering patients who routinely used icodextrin by establishing steady-state plasma concentrations. The model for rats employed a standard three-pore model in which human kinetic parameters were scaled for a rat based on differences in body weight. Both models described the icodextrin molecular weight (MW) distribution as five distinct MW fractions. First order kinetics was applied using degradation rate constants obtained from previous in-vitro measurements using gel permeation chromatography. Ultrafiltration and absorption were predicted during a 4-hour exchange in rats, and 9 and 14-hour exchanges in humans with slow to fast transport characteristics with and without the effect of amylase activity.
In rats, the icodextrin MW profile shifted towards the low MW fractions due to complete disappearance of the MW fractions greater than 27.5 kDa. Including the effect of amylase activity (60 U/L) resulted in 21.1% increase in ultrafiltration (UF) (7.6 mL vs 6.0 mL) and 7.1% increase in icodextrin absorption (CHO) (62.5% with vs 58.1%). In humans, the shift in MW profile was less pronounced. The fast transport (H) patient absorbed more icodextrin than the slow transport (L) patient during both 14-hour (H: 47.9% vs L: 40.2%) and 9-hour (H: 37.4% vs L: 31.7%) exchanges. While the UF was higher during the longer exchange, it varied modestly among the patient types (14-hour range: 460 - 509 mL vs 9-hour range: 382 - 389 mL). When averaged over all patients, the increases in UF and CHO during the 14-hour exchange due to amylase activity (7 U/L) were 15% and 1.5%, respectively.
The icodextrin absorption values predicted by the model agreed with those measured in rats and humans to accurately show the increased absorption in rats. Also, the model confirmed the previous suggestions by predicting an increase in UF specific to amylase activity in dialysate, likely due to the added osmolality by the small molecules generated as a result of the degradation process. As expected, this increase was more pronounced in rats than in humans because of higher dialysate concentrations of amylase in rats.
与超滤相反,关于腹腔内艾考糊精吸收的三孔模型预测尚未见报道,部分原因可能是难以估计透析液中α -淀粉酶活性对葡萄糖聚合物链的降解作用。我们将此降解过程纳入改良的腹膜转运三孔模型,以同时预测大鼠和人类的超滤及艾考糊精吸收情况。
分别构建了人类和大鼠的三孔模型。人类模型改编自PD Adequest 2.0,包括一个从腹腔清除的项,以说明大分子向腹膜组织的吸收,并通过建立稳态血浆浓度来考虑常规使用艾考糊精的患者。大鼠模型采用标准三孔模型,其中根据体重差异将人类动力学参数按比例缩放至大鼠。两个模型均将艾考糊精分子量(MW)分布描述为五个不同的MW级分。使用从先前凝胶渗透色谱体外测量获得的降解速率常数应用一级动力学。在大鼠进行4小时交换期间以及人类具有慢至快转运特征且有或无淀粉酶活性影响的9小时和14小时交换期间预测超滤和吸收情况。
在大鼠中,由于大于27.5 kDa的MW级分完全消失,艾考糊精MW谱向低MW级分偏移。纳入淀粉酶活性(60 U/L)的影响导致超滤(UF)增加21.1%(7.6 mL对6.0 mL),艾考糊精吸收(CHO)增加7.1%(有淀粉酶时为62.5%,无淀粉酶时为58.1%)。在人类中,MW谱的偏移不太明显。在14小时(快速转运(H)患者:47.9%对慢速转运(L)患者:40.2%)和9小时(H:37.4%对L:31.7%)交换期间,快速转运(H)患者比慢速转运(L)患者吸收更多的艾考糊精。虽然在较长时间交换期间超滤较高,但在不同患者类型中变化不大(14小时范围:460 - 509 mL对9小时范围:382 - 389 mL)。在所有患者中平均计算时,14小时交换期间由于淀粉酶活性(7 U/L)导致的超滤和CHO增加分别为15%和1.5%。
该模型预测的艾考糊精吸收值与在大鼠和人类中测量的值一致,准确显示了大鼠吸收的增加。此外,该模型通过预测透析液中特定于淀粉酶活性的超滤增加,证实了先前的推测,这可能是由于降解过程产生的小分子增加了渗透压。正如预期的那样,由于大鼠透析液中淀粉酶浓度较高,这种增加在大鼠中比在人类中更明显。